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Lower respiratory tract infection (LRTI), acute
bronchitis (excluding acute on chronic bronchitis),
chest infection, and acute cough are terms are used
by genera l  pract i t ioners around the wor ld  to
describe a constellation of respiratory symptoms
and signs in patients presenting with acute cough
(Table 1). The severity of illness varies from a dis-
tressing dry cough with a clear chest through to an
influenza-like illness with high fever, sputum and
abnormal chest signs that may suggest community
acquired pneumonia (CAP). 
In Australia, consultation for acute bronchitis is very
common (3.5 per 100 consultations), with antibiotics
being prescribed in about 75% of cases with nearly half
of these having abnormal chest signs or being very
unwell.1 In contrast, the average GP will see approxi-
mately two cases of CAP per 1000 population per
year.2 This figure is similar to the United States with
267 per 100 000 population hospitalised with CAP in
1991 and an overall case fatality rate of 8.8%.3
BACKGROUND Lower respiratory tract infections – acute bronchitis and community acquired pneumonia
(CAP) – are important causes of morbidity in Australia. Acute bronchitis is often treated with antibiotics,
although the cause is usually viral. Community acquired pneumonia may be fatal, particularly in the elderly,
therefore appropriate assessment and management is essential. 
OBJECTIVE This article describes the aetiology, clinical assessment, investigations and management of acute
bronchitis and CAP in the community.
DISCUSSION Clinical assessment is important for acute bronchitis and CAP, with investigations such as C
reactive protein, serology, and chest X-ray informing diagnosis and management of 
the latter. Causative organisms are usually not identified, but are presumed to be viral for acute bronchitis, and
Streptococcus pneumoniae for CAP; although ‘atypicals’ are also important. Antibiotics should generally not be
prescribed for acute bronchitis, however, there is some evidence they may provide limited benefits in patients
who have chest signs, are very unwell, 
are older, have comorbidities, or smoke. In patients with CAP, treated outside of hospital, 
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Cough • THEME
Diagnosis and investigations 
Acute bronchitis
The diagnosis of acute bronchitis is usually clinical
(Case history 1, Table 1). However, if a patient has a
high fever, sore throat and malaise associated with a
cough (productive or otherwise), nasal and throat
swabs for polymerase chain reaction (PCR) may be
appropriate. Chest X-ray should be considered if a
patient has any combination of: 
• heart rate >100 minute
• respiratory rate >24 minute
• temperature >38°C
• night sweats, or 
• focal chest signs. 
Acute bronchitis is associated with bronchial obstruction
and inflammation, so wheezy sounds can often be heard
on auscultation. However, this is usually transitory and
resolves after the infection clears.4 If wheeze has been a
recurrent problem – and a troublesome symptom,
spirometry would be helpful in determining diagnosis. 
General practitioners in Scandinavian countries use
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Case history 1
Mrs Jones, 38 years of age, is a nonsmoking mother of two young
children. Her children have been coughing for a couple of weeks and
are slowly getting better, but now Mrs Jones has developed a cough.
She has some chest discomfort but no fever or sputum. A cough
suppressant has not helped and she wants to know if antibiotics would
be useful. Clinical examination is normal. The viral cause and expected
natural history, including duration of symptoms of her illness is
explained. She is given an information leaflet, encouraged to return if
she develops fever and shortness of breath and is reassured that her
illness is not serious.
Lessons
Acute bronchitis is usually self limiting. Patients should be given
realistic expectations about how long their cough will last (on average
2–3 weeks) and given practical written advice about its management.
Case history 2
Mr Smith, 22 years of age, is a single man
living with his parents. He presented with a flu-
like illness, was examined and told to rest, use
paracetamol every 4 hours and drink plenty of
fluids. Because he was quite unwell, serology
for influenza, full blood count and CRP were
taken. He re-presented to another doctor in the
same practice 2 days later, a CRP of >100 was
noted and bronchial breath sounds (but only
just) on the RLL. Chest X-ray that afternoon
revealed pneumonia. He was commenced on
augmentin and asked to return for review in 
2 days. He developed severe diarrhoea,
attended an emergency department and was
subsequently admitted for 3 days of intra-
venous antibiotics and hydration. He had a
subsequent uneventful recovery.
Lessons
Chest sounds may not always be present, even
if consolidation is found on chest X-ray. CRP 
is a useful test to heighten clinical suspicion.
Augmentin is more likely to cause diarrhoea
than the recommended combination of
amoxicillin plus doxycycline or roxithromycin.
Augmentin does not have activity against the
‘atypicals’.
Table 1. Definition of acute bronchitis
Acute cough of less than 14 days duration with
at least one other respiratory tract symptom





There should be no other obvious cause, 
eg. asthma, sinusitis, COPD
Figure 1. Left lung lower lobe consolidation
point of care C reactive protein (CRP) tests to predict
which patients may benefit from antibiotic. A high and
sustained CRP indicates a more severe and possibly
bacterial infection. Sputum culture is of limited value in
community settings because of nasopharyngeal conta-
mination, and it is thought that outcomes are unrelated
to the identified pathogen.5
CAP
It is not easy to diagnose CAP based solely on the clini-
cal examination (Case history 2) because although the
clinical signs can include fever, productive cough,
tachypnoea, chest pain, crackles or bronchial breath
sounds on auscultation, these may also be absent.
Chest X-ray should be performed in suspected cases.
Unfortunately even the gold standard of chest X-ray –
showing consolidation or infiltrates – may be reported
‘normal’ early in atypical pneumonias (Figure 1). A high
degree of clinical suspicion is helpful in: 
• the elderly 
• those with comorbidities, and 
• those who fail to improve over time. 
In addition to chest X-ray, investigations for suspected
pneumonia should include:
• full blood count (usually normal in viral infections) 
• blood cultures 
• paired serological tests for mycoplasma, chlamydia,
legionella and viral infections if an atypical infection
is suspected, and 
• pertussis serology (in those with persisting cough
especially if presentation occurs during an outbreak). 
Aspiration pneumonia due to anaerobic organisms
should be considered in patients with:
• neurological disorders (eg. mysthenis gravis) 
• dysphagia or oesophageal disease 
• dental sepsis 
• altered consciousness, or 
• terminal illness. 
It should be remembered that the goal of investigations
is to confirm the diagnosis, identify an organism to
guide treatment, and help assess the severity of the
illness throughout management. Follow up radiography
in 2–3 weeks should be performed to exclude any
pathology particularly in (ex)smokers.
Management
Acute bronchitis
Current Australian antibiotic guidelines do not recom-
mend antibiotics for acute bronchitis as it is
predominately of viral origin. Studies have found a
mixed viral, bacterial and atypical picture;6 the usual
pathogens isolated being M. pneumoniae, C. pneumo-
niae and B. pertussis,7–9 although S. pneumoniae, H.
influenzae and M. catarrhalis have also been implicated
in some individuals.9 Nevertheless, systematic reviews
of antibiotic treatment have demonstrated only modest
benefits and these are probably offset by side effects. 
In an effort to identify who may benefit, some GPs
assign prognostic significance to the colour of sputum,
however, there is no evidence the appearance of
sputum is related to bacterial colonisation or the effi-
cacy of antibiotics.10 Chest signs are also used to
determine who may receive antibiotics.11 An association
between the presence of focal chest signs and radi-
ographic pneumonia has been reported,6 although this
does not mean that all patients with chest signs will
benefit from their use. Fever may also be an important
sign, but probably only in association with other factors
such as age, respiratory rate, pulse and comorbidities.12
Clearly those with cough and who are systemically
well, will probably not benefit from antibiotics. For
these patients, GPs can suggest the use of fluids and
paracetamol, along with rest and sickness certification
as appropriate. The use of bronchodilators for acute
bronchitis although common is not supported by recent
research13 and there is not enough evidence for or
against the use of cough suppressants.14 If antibiotics
are expected or requested by the patient, simple
strategies such as delayed prescribing15 and patient
information leaflets16 can reduce antibiotic use and the
frequency of re-consultation. 
Who may benefit from antibiotics?
Those with acute bronchitis and chest signs, who: 
• are very unwell 
• are older (>55) 
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Table 2. Causes of atypical pneumonia
Mycoplasma – occurs in outbreaks with an
incubation period 2–3 weeks. Fever headache
and cough prominent. Chest signs may be
minimal despite radiographic changes
Chlamydia – similar to mycoplasma but does
not occur in epidemics
Legionella – spread via water droplets (potable
water and cooling towers), symptoms include
diarrhoea, high fever, hyponatraemia,
neutrophils but no organisms in gram stain of
respiratory secretions
• have comorbidities, or
• smoke
should be assessed fully as for CAP. Assuming they do
not have CAP, a decision on antibiotics should be made
after discussion with the patient about the potential
benefits and side effects. Clinical review would be
important for this group if symptoms persist or worsen. 
Community acquired pneumonia
Community acquired pneumonia is usually caused by
one organism, most commonly in Australia,
Streptococcus pneumoniae. However, other important
causes include M. pneumoniae, C. pneumoniae and
legionella (Table 2). Although good quality sputum speci-
mens collected before antibiotic therapy can indicate a
likely causative organism, therapy is usually empirical as
outlined in Table 3. Treatment is usually continued for: 
• 5–10 days for bacterial infections 
• 14 days for mycoplasma and chlamydia, and
• 21 days for legionella.
While the choice of antibiotic and duration of treatment
is fairly clear, judging the severity of the illness – and
who needs hospitalisation – requires much clinical
experience. To help, a ‘pneumonia severity index’ (PSI)
has been developed that groups patients with CAP into
one of five classes that reflects expected mortality
(ranges from a 30 day mortality of 0.1% in class one
through to 27% in class five).17
Table 4 shows how to determine if a patient
requires further assessment in hospital. In addition
to intravenous antibiotics, hospitalised patients may
require intravenous fluids, supplementary oxygen,
ana lges ia  for  chest  pa in  and phys iotherapy.
Although hospitalisation is important for those who
are sick, the risk of nosocomial infection should be
considered.
Preventive measures
Few preventive measures are available, however, the
use of influenza and pneumococcal vaccinations in at
risk populations should be encouraged. The National
Health Medical Research Council (NHMRC) recom-
mend that influenza (every year) and pneumococcal
(every 5 years) vaccines be used in those over 65
years of age (over 50 years of age in Aboriginal and
Torres Strait Islanders) and those with chronic dis-
eases. In addition, pneumococcal vaccine should be
given to immunocompromised patients and those
with asplenia.
Conclusion 
Lower respiratory tract infections – acute bronchitis
and CAP – are common and important causes of
morbidity in Australian general practice. Clinical
assessment is important for both conditions with a
limited number of investigations informing diagnosis
and management. Causative organisms are usually
not identified but are presumed to be viral for acute
bronchitis and Strepococcus pneumoniae for CAP,
although ‘atypicals’ are also important. Supportive
treatment is important for both conditions. Although
antibiotics are widely prescribed for acute bronchi-
tis, they should not be used generally. (There is
limited evidence they may be helpful in those with
chest signs, those who are very unwell, older, have
comorbidities or who smoke). In contrast, antibiotic
therapy is indicated for patients with CAP. More
severely unwell patients require hospitalisation and
treatment with intravenous antibiotics. The combi-
nation of amoxycillin and doxycycline/roxithromycin
is appropriate for patients with CAP who are treated
outside of hospital.
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Table 4. CAP: who should be admitted to hospital?
If a patient has one or more of the following they should be considered for
hospitalisation:
• Age >50 years
• Coexisting illness: neoplastic, cerebrovascular, renal, liver or congestive
cardiac failure
• Altered mental state
• Pulse 125 minute
• Respiratory rate 30 minute
• Systolic blood pressure <90 mmHg
• Temperature <35°C or >40°C
Table 3. Treatment of CAP
Class 1 and 2 of the ‘pneumonia severity index’ (patients with more severe
disease, classes 3–5, will require intravenous antibiotics)
Amoxycillin 1 g orally, 8 hourly for 7 days
Plus either:
Doxycycline 200 mg orally, for the first dose, 100 mg per day for a further 
7 days
OR
Roxithromycin 300 mg, daily for 7 days
In patients allergic to penicillin, amoxycillin should be replaced with 
cefuroxime 500 mg orally, 12 hourly for 7 days
Summary of important points
Acute bronchitis
• Most episodes are viral in origin.
• Cough symptoms can last for an average of 
2–3 weeks.
• Bronchodilators and cough suppressants have not
been shown to be effective.
Community acquired pneumonia (CAP)
• Use the pneumonia severity index (PSI) to assess
the need for hospitalisation.
• Outside of hospital, treatment is usually empirical
(amoxycil l in plus either doxycycline or rox-
ithromycin).
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